The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis

Pharmacological Research

Volumn 105, Issue , 2016, Pages 74-83

  Zhang, Zhenhong ^a   Wu, Pingsheng ^a   Zhang, Jiping ^a   Wang, Shunyin ^a   Zhang, Gengxin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

All cause mortality; Meta analysis; Microalbuminuria; Non end stage chronic kidney disease; Proteinuria; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CHRONIC KIDNEY DISEASE; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DISEASE COURSE; END STAGE RENAL DISEASE; EVIDENCE BASED PRACTICE; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; META ANALYSIS; MICROALBUMINURIA; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE ALBUMIN EXCRETION RATIO; UROGENITAL SYSTEM PARAMETERS; ALBUMINURIA; COMPLICATION; DRUG EFFECTS; KIDNEY; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ALBUMINURIA; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC;

EID: 84955279958     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.01.005     Document Type: Review

References (55)

1. W. Hou, J. Lv, V. Perkovic, L. Yang, N. Zhao, M.J. Jardine, and et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis Eur. Heart J. 34 2013 1807 1817
2. G.F. Strippoli, S.D. Navaneethan, D.W. Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 2008 645 651
3. S.D. Navaneethan, F. Pansini, V. Perkovic, C. Manno, F. Pellegrini, D.W. Johnson, and et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis (review) Cochrane Database Syst. Rev. 15 2009 CD007784
4. S. Sandhu, N. Wiebe, L.F. Fried, and M. Tonelli Statins for improving renal outcomes: a meta-analysis J. Am. Soc. Nephrol. 17 2006 2006 2016
5. K. Douglas, P.G. O'Malley, and J.L. Jackson Meta-analysis: the effect of statins on albuminuria Ann. Intern. Med. 145 2006 117 124
6. T.I. Kassimatis, and P.A. Konstantinopoulos The role of statins in chronic kidney disease (CKD): friend or foe Pharmacol. Ther. 122 2009 312 323
7. R. Agarwal Effects of statins on renal function Mayo Clin. Proc. 82 2007 1381 1390
8. A. Hartner, B. Klanke, N. Cordasic, K. Amann, R.E. Schmieder, R. Veelken, and et al. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension J. Hypertens. 27 2009 376 385
9. D.G. Vidt Statin and proteinuria Curr. Atheroscler. Rep. 7 2005 351 357
10. R. Agarwal Statin induced proteinuria: renal injury or renoprotection J. Am. Soc. Nephrol. 15 2004 2502 2503
11. D. de Zeeuw, D.A. Anzalone, V.A. Cain, M.D. Cressman, H.J. Heerspink, B.A. Molitoris, and et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial Lancet Diabetes Endocrinol. 3 2015 181 190
12. C. Baigent, M.J. Landray, C. Reith, J. Emberson, D.C. Wheeler, C. Tomson, and et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
13. M. Rahman, C. Baimbridge, B.R. Davis, J. Barzilay, J.N. Basile, M.A. Henriquez, and et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) Am. J. Kidney Dis. 52 2008 412 424
14. J. Huskey, J. Lindenfeld, T. Cook, G. Targher, J. Kendrick, J. Kjekshus, and et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease Findings from the Scandinavian Simvastatin Survival Study (4S) Atherosclerosis 205 2009 202 206
15. P.A. James, S. Oparil, B.L. Carter, W.C. Cushman, C. Dennison-Himmelfarb, J. Handler, and et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 2014 507 520
16. Chinese Medical Association of hypertension, Chinese Medical Association of hypertension of endocrine and metabolic Committee and Editorial board of the Journal of hypertension. Chinese expert consensus: the screening and intervention of microalbuminuria of patients with hypertension and diabetes mellitus. Chin. J. Hypertens., 2012, 5, 423-428.
17. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PloS Med. 8 2009 e1000097
18. A.R. Jadad, R.A. Moore, D. Carroll, C. Jenkinson, D.J. Reynolds, D.J. Gavaghan, and et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary Control Clin. Trials 17 1996 1 12
19. Higgins, J.P.T, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. Available at http://handbook.cochrane.org/whnjs.htm, 2011.
20. S. Greenland Quantitative methods in the review of epidemiologic literature Epidemiol. Rev. 9 1987 1 30
21. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin. Trials 7 1986 177 188
22. M. Egger, G.D. Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
23. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
24. T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada, and H. Koide Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy Diabetes Care 28 2005 2728 2732
25. M.A. Cadnapaphornchai, D.M. George, K. McFann, W. Wang, B. Gitomer, J.D. Strain, and et al. Effect of pravastatin on total kidney volume, left ventricular mass Index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease Clin. J. Am. Soc. Nephrol. 9 2014 889 896
26. A. Zhang, J. Vertommen, L. Van Gaal, and I. De Leeuw Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients Diabetes Res. Clin. Pract. 29 1995 189 194
27. K.S. Lam, I.K. Cheng, E.D. Janus, and R.W. Pang Cholesterol lowering therapy may retard the progression of diabetic nephropathy Diabetologia 38 1995 604 609
28. T.M. Lee, S.F. Su, and C.H. Tsai Effect of pravastatin on proteinuria in patients with well-controlled hypertension Hypertension 40 2002 67 73
29. T.M. Lee, M.S. Lin, C.H. Tsai, and N.C. Chang Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers Kidney Int. 68 2005 779 787
30. T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, T. Inoue, N. Shimada, and et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis Nephrol. Dial. Transplant. 17 2002 798 802
31. S. Bianchi, R. Bigazzi, A. Caiazza, and V.M. Campese A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am. J. Kidney Dis. 41 2003 565 570
32. Y. Imai, H. Suzuki, T. Saito, I. Tsuji, K. Abe, and T. Saruta The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia: Pravastatin and Renal Function Research Group Clin. Exp. Hypertens. 21 1999 1345 1355
33. G. Yasuda, T. Kuji, K. Hasegawa, N. Ogawa, G. Shimura, D. Ando, and et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease Ren. Fail. 4 2004 411 418
34. Robert G. Fassett, Iain K. Robertson, and Madeleine J. Ball Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial Atherosclerosis 213 2010 218 224
35. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial J. Am. Coll. Cardiol. 55 2010 1266 1273
36. P.W. Nanayakkara, C. van Guldener, P.M. ter Wee, P.G. Scheffer, F.J. van Ittersum, J.W. Twisk, and et al. Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Anti-Oxidant Therapy in Chronic Renal Insufficiency (ATIC) Study Arch. Intern. Med. 167 2007 1262 1270
37. M. Tonelli, C. Isles, G.C. Curhan, A. Tonkin, M.A. Pfeffer, J. Shepherd, and et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 2004 1557 1563
38. F.W. Asselbergs, G.F. Diercks, H.L. Hillege, A.J. van Boven, W.M. Janssen, A.A. Voors, and et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria Circulation 110 2004 2809 2816
39. B.L. Rayner, M.J. Byrne, and R. van Zyl-Smit A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone Clin. Nephrol. 46 1996 219 224
40. M. Chonchol, T. Cook, J. Kjekshus, T.R. Pedersen, and J. Lindenfeld Simvastatin for secondary prevention of all cause mortality and major coronary events in patients with mild chronic renal insufficiency Am. J. Kidney Dis. 49 2007 373 382
41. A. Verma, K.M. Ranganna, R.S. Reddy, M. Verma, and N.F. Gordon Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease Am. J. Cardiol. 96 2005 1290 1292
42. P.A. Lemos, P.W. Serruys, P. de Feyter, N.F. Mercado, D. Goedhart, F. Saia, and et al. Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes(a LIPS substudy) Am. J. Cardiol. 95 2005 445 451
43. M.J. Koren, M.H. Davidson, D.J. Wilson, R.S. Fayyad, A. Zuckerman, D.P. Reed, and et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD Am. J. Kidney Dis. 53 2009 741 750
44. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, and et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am. J. Kidney Dis. 54 2009 810 819
45. H. Nakamura, K. Mizuno, Y. Ohashi, T. Yoshida, K. Hirao, and Y. Uchida MEGA study group. Pravastatin and cardiovascular risk in moderate chronic kidney disease Atherosclerosis 206 2009 512 517
46. A. Özyilmaz, S.J. Bakker, D. de Zeeuw, P.E. de Jong, and R.T. Gansevoort PREVEND study group. Selection on a albuminuria enhance the efficacy of screening for cardiovascular risk factor Nephrol. Dial. Transplant. 25 2010 3560 3568
47. A. Verhulst, P.C. D'Haese, and M.E. De Broe Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells J. Am. Soc. Nephrol. 15 2004 2249 2257
48. J.E. Sidaway, R.G. Davidson, F. McTaggart, T.C. Orton, R.C. Scott, G.J. Smith, and et al. Inhibitors of 3-hydroxy-methylgutary-CoA reductase reduce receptor-mediated endocytosis in oppssum kidney cells J. Am. Soc. Nephrol. 15 2004 2258 2265
49. V.M. Alla, V. Agrawal, A. DeNazareth, S. Mohiuddin, S. Ravilla, and M. Rendell A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs Drugs 73 2013 1025 1054
50. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012, 380, 581-590.
51. H. Naci, J.J. Brugts, R. Fleurence, B. Tsoi, H. Toor, and A.E. Ades Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur. J. Prev. Cardiol. 20 2013 641 657
52. Q. Geng, J. Ren, J. Song, S. Li, and H. Chen Meta-analysis of the effect of statins on renal function Am. J. Cardiol. 114 2014 562 570
53. S.C. Palmer, S.D. Navaneethan, J.C. Craig, D.W. Johnson, V. Perkovic, J. Hegbrant, and et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst. Rev. 31 2014 CD007784
54. J.P. Ioannidis, and J. Lau Pooling research results: Benefits and limitations of meta-analysis Jt. Comm. J. Qual. Improv. 25 1999 462 469
55. Christoph Wanner, and Marcello Tonelli The kidney disease: improving global outcomes lipid guideline development work group members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient Kidney Int. 85 2014 1303 1309